New saccharide derivatives of indolo[2,3-b]quinoline as cytotoxic compounds and topoisomerase II inhibitors

Radiology and Oncology

Volumn 38, Issue 2, 2004, Pages

  Godlewska, Joanna ^a,b   Badowska Rosłonek, Katarzyna ^b   Ramza, Jan ^b   Kaczmarek, Łukasz ^b   Peczyńska Czoch, Wanda ^c   Opolski, Adam ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

DNA topoisomerases, type II antagonists and inhibitors; Indols; Quinones

Indexed keywords

2 DEOXY ALPHA DEXTRO GLUCOPYRANOSIDE; 2 DEOXY ALPHA DEXTRO LACTOPYRANOSIDE; 2 DEOXY ALPHA LEVO RHAMNOPYRANOSIDE; 6H INDOLO[2,3 B]QUINOLINE DERIVATIVE; ALPHA LEVO ACOSAMINIDE; ALPHA LEVO DAUNOSAMINIDE; AMINOSUGAR; CARBOHYDRATE; DAUNOSAMINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; GLUCOSE; INDOLE DERIVATIVE; INDOLO[2,3 B]QUINOLINE DERIVATIVE; LACTOSE; QUINOLINE DERIVATIVE; RHAMNOSE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; SYNTHESIS; T CELL LEUKEMIA; UTERINE CERVIX CARCINOMA;

EID: 3142686692     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jonckers TH, van Miert S, Cimanga K, Bailly C, Colson P, De Pauw-Gillet MC, et al. Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives. J Med Chem. 2002; 45(16): 3497-508.
2. Dassonneville L, Lansiaux A, Wattelet A, Wattez N, Mahieu C, Van Miert S, et al. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur J Pharmacol. 2000; 409(1): 9-18.
3. Awada A, Giacchetti S, Gerard B, Eftekhary P, Lucas C, De Valeriola D, et al. Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Ann Oncol. 2002; 13(12): 1925-34.
4. Pognan F, Saucier JM, Paoletti C, Kaczmarek L, Nantka-Namirski P, Mordarski M, et al. A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. Biochem Pharmacol. 1992; 44(11): 2149-55.
5. Peczynska-Czoch W, Pognan F, Kaczmarek L, Boratynski J. Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: novel cytotoxic, DNA topoisomerase II inhibitors. J Med Chem. 1994; 37(21): 3503-10.
6. Kaczmarek L, Peczynska-Czoch W, Osiadacz J, Mordarski M, Sokalski WA, Boratynski J, et al. Synthesis, and cytotoxic activity of some novel indolo[2,3-b]quinoline derivatives: DNA topoisomerase II inhibitors. Bioorg Med Chem 1999; 7(11): 2457-64.
7. Kaczmarek L, Luniewski W, Zagrodzki B, Godlewska J, Osiadacz J, Wietrzyk J, et al. Synthesis of 6-substituted 6H-indolo[2,3-b]quinolines as novel cytotoxic agents and topoisomerase II inhibitors. Acta Pol Pharm 2002; 59(3): 199-207.
8. Kaczmarek L, Peczynska-Czoch W, Opolski A, Wietrzyk J, Marcinkowska E, Boratynski J, et al. Methoxy- and methyl-, methoxy-5,6,11-trimethyl-6H-indolo [2,3-b]quinolinium derivatives as novel cytotoxic agents and DNA topoisomerase II inhibitors. Anticancer Res 1998; 18(4C): 3133-8.
9. Kociubinska A, Gubernator J, Godlewska J, Stasiuk M, Kozubek A, Peczynska-Czoch W, et al. A derivative of 5H-indolo[2,3-b]quinoline - a novel liposomally-formulated anticancer agent. Cell Mol Biol Lett 2002; 7(2): 289.
10. K. Badowska-Rosłonek, L. Kaczmarek, J. Ramza, W. Szelejewski, J. Godlewska, W. Peczyńska-Czoch; Polish Patent Application P-353811 Warsaw 2002.
11. Muller MT, Spitzner JR, DiDonato JA, Mehta VB, Tsutsui K, Tsutsui K. Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 1988; 27(22): 8369-79.
12. Muller MT, Helal K, Soisson S, Spitzner JR. A rapid and quantitative microtiter assay for eukaryotic topoisomerase II. Nucleic Acids Res 1989; 17(22): 9499.
13. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
14. Boyd MR. Status of the NCI Preclinical Antitumor Agent Discovery Screen, Principles and Practice of Oncology Updates. 1989; 3(10): 1-12, Appendix XVI.